Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Orexigen Therapeutics, Inc. (OREX) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Orexigen Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1382911.
Total stock buying since 2014: $420,486.
Total stock sales since 2014: $1,966,678.
Total stock option exercises since 2014: $670,690.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2018 | 0 | $0 | 2,228,533 | $22,674 | 0 | $0 |
| 2016 | 0 | $0 | 800 | $1,568 | 0 | $0 |
| 2015 | 0 | $0 | 50,000 | $284,200 | 50,000 | $83,000 |
| 2014 | 83,377 | $420,486 | 354,031 | $1,658,236 | 354,031 | $587,690 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2018-10 | 0 | $0 | 2,226,839 | $22,268 | 0 | $0 |
| 2018-03 | 0 | $0 | 1,694 | $406 | 0 | $0 |
| 2016-12 | 0 | $0 | 800 | $1,568 | 0 | $0 |
| 2015-02 | 0 | $0 | 50,000 | $284,200 | 50,000 | $83,000 |
| 2014-12 | 0 | $0 | 22,643 | $135,858 | 22,643 | $37,587 |
| 2014-11 | 28,377 | $157,936 | 31,388 | $182,878 | 31,388 | $52,103 |
| 2014-09 | 55,000 | $262,550 | 300,000 | $1,339,500 | 300,000 | $498,000 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-10-31 | Klarman Seth A | Sale | 896,339 | .01 | 8,963 |
| 2018-10-29 | Klarman Seth A | Sale | 650,000 | .01 | 6,500 |
| 2018-10-25 | Klarman Seth A | Sale | 652,500 | .01 | 6,525 |
| 2018-10-24 | Klarman Seth A | Sale | 28,000 | .01 | 280 |
| 2018-03-15 | Moglia Stephen A. (VP & Chief Accounting Officer) | Sale | 1,694 | .24 | 406 |
| 2016-12-19 | Moglia Stephen A. (VP, Chief Accounting Officer) | Sale | 800 | 1.96 | 1,568 |
| 2015-02-26 | Booth Mark D (Chief Commercial Officer) | Sale | 50,000 | 5.68 | 284,200 |
| 2015-02-26 | Booth Mark D (Chief Commercial Officer) | Option Ex | 50,000 | 1.66 | 83,000 |
| 2014-12-02 | Turner Heather D (SVP, Gen. Counsel & Secretary) | Sale | 22,643 | 6.00 | 135,858 |
| 2014-12-02 | Turner Heather D (SVP, Gen. Counsel & Secretary) | Option Ex | 22,643 | 1.66 | 37,587 |
| 2014-11-25 | Turner Heather D (SVP, Gen. Counsel & Secretary) | Sale | 7,382 | 6.00 | 44,292 |
| 2014-11-25 | Turner Heather D (SVP, Gen. Counsel & Secretary) | Option Ex | 7,382 | 1.66 | 12,254 |
| 2014-11-24 | Turner Heather D (SVP, Gen. Counsel & Secretary) | Sale | 24,006 | 5.77 | 138,586 |
| 2014-11-24 | Turner Heather D (SVP, Gen. Counsel & Secretary) | Option Ex | 24,006 | 1.66 | 39,849 |
| 2014-11-18 | Bock Louis C (Director) | Buy | 1,325 | 5.58 | 7,392 |
| 2014-11-12 | Bock Louis C (Director) | Buy | 27,052 | 5.57 | 150,544 |
| 2014-09-22 | Turner Heather D (VP, Gen. Counsel & Secretary) | Sale | 300,000 | 4.46 | 1,339,500 |
| 2014-09-22 | Turner Heather D (VP, Gen. Counsel & Secretary) | Option Ex | 300,000 | 1.66 | 498,000 |
| 2014-09-15 | Hagan Joseph P (Sr. VP, Corporate Development) | Buy | 5,000 | 4.69 | 23,450 |
| 2014-09-15 | Narachi Michael (President and CEO) | Buy | 50,000 | 4.78 | 239,100 |
Insider trading activities including stock purchases, stock sales, and option exercises of OREX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Orexigen Therapeutics, Inc. (symbol OREX, CIK number 1382911) see the Securities and Exchange Commission (SEC) website.